5th Expanded Access Programmes World Congress 2023 Americas
Day 2 - Friday 17th November 2023
Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
ACCESS & COMMERCIALIZATION
- Deep-dive into the reality of healthcare access around the world
- Streamlining the process and navigating early access regulations globally
- What does the future of health access look like? The interconnected ecosystem where all healthcarestakeholders work together
Panelists:
Jennifer E. Miller, PhD, Associate Professor, Yale School of Medicine
Monica L Weldon, President/CEO/Founde, SYNGAP1 Foundation
- Ideal Accelerated Pathway
- Problems of Excluding Some Disease
- Brainstorming: Removing the Barriers
- What’s the Long Game?: Rethinking the Regulatory Rules
Monica L Weldon, President/CEO/Founde, SYNGAP1 Foundation
- Building access specific competencies in emerging Market Medical Affairs
- Pivotal role of Early Access Programs
Siddharth Jain, Medical Director –LSDs & HAE, Global Medical Affairs, Takeda
- Companies should anticipate the need for EA and should have a written policy
- The policy should be available to the person entitled to expanded access
- Companies must be accountable to the patients sending expanded access requests
- Sharing of data analysis is crucial for improvement
Donna Cowan, Associate Director, EAP & Registry, Stealth Biotherapeutics*
- The importance of patient advocacy in providing much-needed information on EAP’s available for patients
- Collaborating with one another to enable a much richer understanding of patient needs
- Patient groups’ importance in working with health authorities to advance policies that accelerate patientaccess to investigational medicine
- Creating a state of the art payer engagement strategies to address challenges in pricing and reimbursement
Moderator:
Panelist:
Misty Gravelin, Project Lead, Expanded Access Support Unit, University of Michigan
Alan J. Balch, Chief Executive Officer, Patient Advocate Foundation Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
MULTI-STAKEHOLDER APPROACH & COLLABORATION
- Challenges & Opportunities of a company-wide roll-out of Early Access Programme
Strategies & consideration for a successful implementation
Established responsibilities from everyone involved to ensure smooth delivery to patients in need
- The importance of patient advocacy in providing much-needed information on EAP’s available for patients
- Collaborating with one another to enable a much richer understanding of patient needs
- Patient groups’ importance in working with health authorities to advance policies that accelerate patient access to investigational medicines
- Creating a state of the art payer engagement strategies to address challenges in pricing and reimbursement
Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
- Interaction between pharmaceutical companies and healthcare providers could foster the development of new medicines which will ultimately benefit patients.
- Would this enhance technological innovation, fosters knowledge creation, aids disease control, and reducespolypharmacy issues?
- Guidelines to help professionals navigate the opposing explanations of interactions with pharmaceutical companies
- The importance of patient advocacy in providing a much-needed information on EAP’s available for patients
- Collaborating with one another to enable a much richer understanding of patient needs
- Patient groups importance in working with health authorities to advance policies that accelerates patientaccess to investigational medicines
- Creating a state-of the art payer engagement strategies to address challenges in pricing and reimbursement
END OF CONFERENCE